Latest News in the pharma Industry
Research & Development
Common antimicrobials help patients recover from MRSA abscesses
3 Jul 2017
NIAID-funded trial counters current thinking about treatment effectiveness.
Read more
Novartis receives EU approval for first-line use of Zykadia in ALK-positive advanced NSCLC
29 Jun 2017
In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival compared with SOC chemotherapy with maintenance.
Read more
Researchers develop microneedle patch for flu vaccination
28 Jun 2017
The patch can dramatically reduce the cost of vaccination, as self-administration can eliminate the need to have health workers oversee the process.
Read more
Merck's anacetrapib meets primary endpoint
28 Jun 2017
Company to consider whether to file new drug applications with the FDA and other regulatory agencies.
Read more
Cladribine Tablets receives positive CHMP opinion for treatment of relapsing forms of MS
25 Jun 2017
Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical trials.
Read more
Pfizer receives expanded Health Canada approval for Ibrance in HR+, HER2- metastatic breast cancer
25 Jun 2017
New indication supported by results of Phase III PALOMA-3 Trial of Ibrance in combination with fulvestrant.
Read more
Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by CHMP
23 Jun 2017
If approved, Imraldi will be the third anti-TNF biosimilar in Biogen’s portfolio in Europe.
Read more
Novartis achieves regulatory milestone for AMG 334 in migraine prevention with EMA filing acceptance
21 Jun 2017
AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance.
Read more
FDA accepts Amgen's sBLA to expand indication for Xgeva to include multiple myeloma patients
19 Jun 2017
Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumours and is the number one prescribed agent by oncologists for this indication in the US.
Read more
Merck presses the pause button on Keytruda trials
16 Jun 2017
The pause is to allow for additional information to be collected to better understand more reports of death in the Keytruda groups.
Read more
Parexel and Sanofi collaborate to advance the use of wearable devices in life science industry
15 Jun 2017
Preliminary findings from pilot study validate use of wearable technologies to collect data and manage clinical trials more effectively and efficiently.
Read more
Lilly's Taltz shows promise for patients with active psoriatic arthritis
15 Jun 2017
Demonstrated significant improvements in disease signs and symptoms at 24 weeks among patients with active psoriatic arthritis who had prior inadequate response or intolerance to TNF inhibitors.
Read more